James Quigley
Stock Analyst at Goldman Sachs
(0.52)
# 3,793
Out of 4,818 analysts
21
Total ratings
50%
Success rate
-25.02%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Initiates: Neutral | $65 | $53.02 | +22.60% | 1 | Mar 21, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $45 → $49 | $30.89 | +58.63% | 5 | Nov 6, 2024 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $110.13 | +9.87% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $7.16 | +46.65% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $25.50 | +56.86% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.08 | +292.16% | 3 | Jun 23, 2023 |
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $53.02
Upside: +22.60%
Kymera Therapeutics
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $45 → $49
Current: $30.89
Upside: +58.63%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $110.13
Upside: +9.87%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $7.16
Upside: +46.65%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $25.50
Upside: +56.86%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.08
Upside: +292.16%